Atlas · Symbols · Stocks & Shares · AMRZ
Equity · United States

Amrize Ltd AMRZ

Amrize Ltd is a cement, hydraulic issuer listed as AMRZ on NYSE. This free Atlas page links SEC CIK 2035989, Nasdaq Trader and TradingView NYSE:AMRZ, related symbols and the workstation route before a full report is run.

At a glance

AMRZ public profile

Business

Cement, hydraulic issuer. Atlas tracks AMRZ through its NYSE listing record, chart route and source links.

Listing

AMRZ trades on NYSE. SEC CIK 2035989. Chart route NYSE:AMRZ.

Browse

Nasdaq Trader is the listing identity source for Amrize Ltd. Atlas files AMRZ under USA Stocks for browsing. The canonical public URL is /stocks/AMRZ/. The workstation link below opens the fuller research run.

Market Wit preview

Amrize arrives with a pleasingly blunt first-quarter problem: the business has real scale, real products, and real losses in the same filed envelope. The 10-Q for the period ending 2026-03-31 shows revenue from contracts with customers of $2.18B, assets of $24.27B, cash of $1.10B, and diluted EPS of $-0.21. That is not a ghost company with a logo and a meeting room. It is an operating business with inventory, capex and warranty accruals, which means the story has to leave the slogan and walk into the yard where costs live. The official site says the company rises to build customers' ambitions; the filing says operating income was $-76.0M. Ambition is allowed, but it has apparently been asked to bring receipts and a hard hat. (source: SEC EDGAR 10-Q...

Run the full workstation report for the complete source rail, saved history, export controls, and the full Market Wit file for AMRZ.

Run full research Go Atlas Pro

Daily answer

What changed for Amrize Ltd today

Open full report
AMRZ daily contextvalidated public digest15 source rail2026-06-20 14:03 UTC

Amrize Ltd's current file is led by a hard contrast: the official issuer rail says the company launched a $1 Billion share buyback programme and grew first-quarter revenue 4.7% while reaffirming 2026 guidance, but the latest SEC 10-Q shows a first-quarter net loss attributable to parent of $-116.0M and diluted EPS of $-0.21 for the period ending 2026-03-31. That is the central equity tension in AMRZ today: scale and confidence language on one side, negative earnings and operating cash use on the other.

The company presents itself through the official line, "Across Amrize, we rise to build our customers' greatest ambitions," and the supplied source rail includes a product and brand catalogue image from the issuer site. That proves an operating-business story rather than a pure ticker story: AMRZ is being framed by its own materials around customers, products and growth in footprint. The 10-Q adds that Amrize strategically acquires companies to increase its footprint and offer products that diversify its business, but the supplied evidence does not name specific products, end markets or customers beyond that official rail.

The filed financials are substantial. In the SEC EDGAR 10-Q for the period ending 2026-03-31, Amrize reported revenue from contracts with customers of $2.18B, operating income of $-76.0M, net income attributable to parent of $-116.0M, assets of $24.27B, liabilities of $11.18B, and stockholders' equity attributable to parent of $13.09B. Cash and cash equivalents stood at $1.10B. Net cash used in operating activities was $-896.0M, payments to acquire property, plant and equipment were $272.0M, inventory net was $1.57B, and the standard product warranty accrual increase for warranties issued was $27.0M.

The source route here is filing-led rather than chart-led. The evidence supplies SEC EDGAR filings, the issuer site, the SEC submissions JSON, and the SEC companyfacts JSON, but it does not supply a chart route, price level, moving average, volume figure or TradingView context. That means the market mechanism in this report is not candle-reading. It is the public-company mechanism: quarterly numbers, cash use, capital spending, inventory, warranty accruals, buyback messaging, guidance language, and a sequence of Form 4 insider-reporting filings.

What changed in the public record is specific. The 8-K dated 2026-04-29 says Amrize issued a press release announcing financial results for the quarter ended 2026-03-31 and prepared an investor presentation for investors.amrize.com. The 8-K dated 2026-04-21 records approval of the annual report, including consolidated and statutory financial statements for fiscal year 2025. SEC Form 4 filings then followed on 2026-05-07, 2026-05-18, 2026-05-20, two on 2026-05-21, and 2026-05-26. Those filings matter because they keep the post-results governance and ownership trail on the official rail.

What remains unproven is just as important. The supplied evidence does not include a live share price, valuation multiple, debt maturity schedule, segment-level margin bridge, named acquisition detail, customer mix, order book, dividend declaration or management transcript. A deeper file would be changed by official evidence that connects the $1 Billion buyback, the reaffirmed 2026 guidance, the $-896.0M operating cash flow figure and the company's acquisition strategy into one reconciled capital-allocation story.

This is the public answer layer. The full Atlas report adds the complete Market Wit archive, risk rail, catalyst map, final editor synthesis, PDF/CSV export, email delivery and saved history.

Ticker
AMRZ
Exchange
NYSE
Sector
Us Public Equity Directory
Region
United States
Asset class
Equity
Directory source
Nasdaq Trader
SEC CIK
TradingView
Source authority

AMRZ evidence rails

Atlas uses the specific public rails available for AMRZ: SEC EDGAR, Nasdaq Trader, TradingView, FRED. Source names identify evidence routes and tools; no partnership, sponsorship or endorsement is implied.

TradingView chart NYSE:AMRZ

Atlas has no approved static OHLC cache attached for AMRZ yet, so the profile renders the verified TradingView chart route directly and keeps the full-chart link as fallback.

Open full TradingView chart ->

Run an Atlas research workflow on AMRZ

FreedomCore Atlas operates research workstation templates for company snapshots, DCF, LBO, KYC, NAV tie-outs, and council-grade equity briefs. Each workflow uses public-source filings and structured prompts.

Open Atlas workstation ->
Atlas Pro

Save AMRZ research and exports

Free Atlas users can run full browser research reports from the workstation. Atlas Pro adds 25 custom runs a day, saved research history, email delivery, PDF/CSV exports, and a 25-symbol watchlist. £12/mo founding price, locked for life. Research only; not investment advice.

Checking Atlas access...

AMRZ FAQ

What is Amrize Ltd (AMRZ)?Amrize Ltd is a cement, hydraulic issuer listed as AMRZ on NYSE. This free Atlas page links SEC CIK 2035989, Nasdaq Trader and TradingView NYSE:AMRZ, related symbols...

Amrize Ltd is a cement, hydraulic issuer listed as AMRZ on NYSE. This free Atlas page links SEC CIK 2035989, Nasdaq Trader and TradingView NYSE:AMRZ, related symbols and the workstation route before a full report is run.

What does Atlas show for AMRZ?The AMRZ page gives the free Atlas profile for Amrize Ltd: listing identity, chart route, related symbols, source authority and the workstation route. The chart route...

The AMRZ page gives the free Atlas profile for Amrize Ltd: listing identity, chart route, related symbols, source authority and the workstation route. The chart route is NYSE:AMRZ; the stable page route is /stocks/AMRZ/. Visible source links include SEC EDGAR CIK 2035989, Nasdaq Trader and TradingView NYSE:AMRZ. Atlas files AMRZ under USA Stocks for browsing.

How often is the AMRZ page updated?The /stocks/AMRZ/ URL is stable. Atlas updates the free AMRZ page when the symbol-universe record, listing identity, source links, chart route, related-symbol links or...

The /stocks/AMRZ/ URL is stable. Atlas updates the free AMRZ page when the symbol-universe record, listing identity, source links, chart route, related-symbol links or published public answer changes.

Which sources does Atlas use for AMRZ?For AMRZ, Atlas starts with SEC EDGAR CIK 2035989, Nasdaq Trader and TradingView NYSE:AMRZ. The SEC CIK 2035989 route is the issuer filing anchor. Nasdaq Trader...

For AMRZ, Atlas starts with SEC EDGAR CIK 2035989, Nasdaq Trader and TradingView NYSE:AMRZ. The SEC CIK 2035989 route is the issuer filing anchor. Nasdaq Trader confirms the listed-symbol identity used by the public directory. NYSE:AMRZ is the chart route shown on the free page. Full workstation reports may add fresh filings, issuer documents, holdings, news, macro context or model-reviewed notes when available.

Can Atlas run a full research brief on AMRZ?Yes. The workstation can open AMRZ, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.

Yes. The workstation can open AMRZ, expand the public source set into a fuller browser report, and add email, PDF or CSV export where the account tier allows it.

Is this AMRZ page investment advice?No. The AMRZ page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a buy or sell instruction, or a...

No. The AMRZ page is a research and source-navigation page. It does not provide personalised financial advice, brokerage execution, a buy or sell instruction, or a promise of returns.

Methodology

This profile is generated daily from public sources including SEC EDGAR (US-listed companies), NASDAQ Trader files, exchange listings, public macro/central-bank releases, CoinGecko crypto market files where relevant, and the TradingView global symbol catalog. Multi-model AI may assist drafting and review where configured, but sources remain the evidence rail; the chart is an Atlas static OHLC rail with a live TradingView link.

Research only. Not investment advice. No brokerage execution. No guaranteed returns are promised or implied. FreedomCore does not provide personalised investment advice. Always consult a regulated financial advisor before making investment decisions.

Profile last updated: 2026-06-20. Browse FreedomCore Atlas research notes →